Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
13.11.2024 18:00:00 CET | Business Wire | Press release
Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.
For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.
“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences.
Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market.
Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.
To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched Unveiling the Invisible, a video campaign that showcases how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.
View the fascinating video series here.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113252394/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Simon-Kucher Selects Navan to Modernize Global Travel Program24.2.2026 11:00:00 CET | Press release
Global consultancy to consolidate travel operations with Navan across more than a dozen markets Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Simon-Kucher, the world’s leading commercial growth and pricing consultancy, as its global travel partner. Simon-Kucher teams will now have access to Navan’s AI-powered travel management platform across more than a dozen markets, including in the North American, European, and APAC regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224745907/en/ Simon-Kucher Selects Navan to Modernize Global Travel Program “Our work is increasingly global, and travel remains essential to how we collaborate with clients and with one another,” said Thomas Wohlan, Director of Travel Management at Simon-Kucher. “To support that at scale, we needed a modern travel platform that brings consistency across countries and simplifi
Khazna Awarded Uptime Tier III Certification of Design Documents for Ajman, UAE Facility, Largest in Company’s Portfolio24.2.2026 10:00:00 CET | Press release
Set to Achieve 1st Certified AI Data Center with Liquid Cooling in Middle East Uptime Institute, the Global Digital Infrastructure Authority, today announced that Khazna Data Centers, a global leader in hyperscale digital infrastructure, has achieved the Uptime Institute Tier III Certification of Design Documents (TCDD) award for its newest 100 MW AI-optimized data center, QAJ01 —set to be the first certified AI data center with liquid cooling in the Middle East and North Africa region. Representing the largest facility in Khazna’s portfolio, this state-of-the-art development features 20 data halls, each delivering 5 MW of IT capacity, purpose-built to meet the demands of next-generation artificial intelligence (AI) workloads. The certification underscores Khazna’s commitment to designing world-class, resilient, and efficient data center infrastructure in alignment with the industry’s most rigorous global standards. Located in Ajman, United Arab Emirates, the new facility has been desi
Infobip and ESA Boost Asteroid Impact Alerts with Instant Voice Calls24.2.2026 10:00:00 CET | Press release
New partnership accelerates response times for critical planetary defense alerts Global cloud communications platform, Infobip, has partnered with the European Space Agency (ESA) to improve the delivery of asteroid impact alerts via Infobip's Voice API solutions. Using Infobip’s platform, ESA personnelnow receive instant voice calls, enabling faster, 24/7 alerts for potential asteroid impacts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224294384/en/ European Space Agency partners with Infobip for asteroid impact alerts. Understanding the trajectories of asteroids, particularly those approaching Earth, known as near-Earth objects (NEOs), is crucial and time sensitive. As single asteroid impact 65 million years ago wiped out most life on Earth, it is vital for the ESA to identify all hazardous asteroids to better understand their physical characteristics and the potential consequences of an impact. Previously, ESA perso
ElevenEs held 1st Closing of its Series B Investment Round Backed by Caterpillar Venture Capital Inc.24.2.2026 09:24:00 CET | Press release
Construction of its 1GWh LFP Battery Cell Mega Factory to Begin in February 2026. ElevenEs has completed the first closing of its Series B investment round, backed by Caterpillar Venture Capital Inc., a wholly owned subsidiary of Caterpillar Inc. (NYSE: CAT) - the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Additionally, an affiliate of BST (HK) Ltd., a leading Hong Kong-based commodity trading house, participated in the round. This transaction represents a significant milestone in the future of European battery manufacturing as the proceeds will be used for the initial phases of infrastructure and equipment toward the planned 1GWh Mega-Factory, with construction starting in February 2026. The first battery cell deliveries are expected in 2027. This project positions ElevenEs at the forefront of the global energy transition and marks a significant step forward in
PUR Appoints Dr. Daniel Klier as Chief Executive Officer24.2.2026 09:00:00 CET | Press release
Seasoned sustainability and climate finance leader to guide PUR’s next phase of growth PUR (the “Company”), a pioneer in Nature-based Solutions, today announced the appointment of Dr. Daniel Klier as Chief Executive Officer, subject to regulatory approval. Founded nearly two decades ago, PUR partners with farming communities globally to deliver agroforestry, reforestation, and landscape restoration projects. The Company generates verified carbon reductions and carbon credits that help corporates reduce supply chain emissions through high-integrity insetting and climate contributions within and beyond their own value chains, while improving soil health, water resources, and long-term farm productivity. PUR is a recognized leader in resilient coffee and cocoa value chains, reforestation, mangrove restoration, and ecosystem conservation, delivering measurable benefits for ecosystems, agriculture, and farming communities. Dr. Klier’s appointment marks the next phase of PUR’s development as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom